SGLT-2 inhibitors - An assessment of the German oral therapeutic landscape for people with type 2 diabetes

被引：0

作者：

Aberle, Jens ^{[1
]}

Blueher, Matthias ^{[2
]}

Laudes, Matthias ^{[3
]}

Merkel, Martin ^{[4
]}

Sandow, Petra ^{[5
]}

机构：

[1] Univ Klinikum Hamburg Eppendorf, Endokrinol & Diabetol, Univ Adipositaszentrum Hamburg, Hamburg, Germany

[2] Univ Med Leipzig, Helmholtz Inst Metab Adipositas & Gefassforsch HI, Leipzig, Germany

[3] Univ Klinikum Schleswig Holstein, Med Klin 1, Kiel, Germany

[4] Endokrinol Hamburg, Internist Endokrinol Diabetol, Hamburg, Germany

[5] Praxis, Allgemeinmed, Berlin, Germany

来源：

DIABETOLOGIE UND STOFFWECHSEL | 2025年 / 20卷 / 01期

关键词：

SGLT2; type; 2; diabetes; therapy; prevention; comparison; POST-HOC ANALYSES; CARDIOVASCULAR OUTCOMES; KIDNEY-DISEASE; DAPAGLIFLOZIN; MELLITUS; PREVENTION; EFFICACY; PLACEBO; SAFETY;

D O I：

10.1055/a-2549-1472

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

As numerous extensive studies have shown, SGLT2 inhibitors not only have beneficial effects on glucose metabolism, but also have a pronounced protective effect on the heart and kidneys. This class of drugs therefore plays an important role in the primary and secondary prevention of diabetes-associated comorbidities. Based on the evidence for SGLT2 inhibitors, guidelines recommend their early use in people with type 2 diabetes being at high risk of cardiovascular and/or renal events. However, prescription data show that these recommendations are currently not implemented and that significantly more people with type 2 diabetes could benefit from organ-protective therapy. Therefore, the aim of this review is to present the value of SGLT2 inhibitors in comparison to other oral therapeutic approaches for the treatment of type 2 diabetes.

引用

页码：59 / 70

页数：12

共 92 条

[61] Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial [J].

Mosenzon, Ofri ;

Raz, Itamar ;

Wiviott, Stephen D. ;

Schechter, Meir ;

Goodrich, Erica L. ;

Yanuv, Ilan ;

Rozenberg, Aliza ;

Murphy, Sabina A. ;

Zelniker, Thomas A. ;

Langkilde, Anna Maria ;

Gause-Nilsson, Ingrid A. M. ;

Fredriksson, Martin ;

Johansson, Peter A. ;

Wilding, John P. H. ;

McGuire, Darren K. ;

Bhatt, Deepak L. ;

Leiter, Lawrence A. ;

Cahn, Avivit ;

Dwyer, Jamie P. ;

Heerspink, Hiddo J. L. ;

Sabatine, Marc S. .

DIABETES CARE, 2022, 45 (10) :2350-2359

[62] Euglycemic diabetic ketoacidosis: A missed diagnosis [J].

Nasa, Prashant ;

Chaudhary, Sandeep ;

Shrivastava, Pavan Kumar ;

Singh, Aanchal .

WORLD JOURNAL OF DIABETES, 2021, 12 (05) :514-523

[63] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes [J].

Neal, Bruce ;

Perkovic, Vlado ;

Mahaffey, Kenneth W. ;

de Zeeuw, Dick ;

Fulcher, Greg ;

Erondu, Ngozi ;

Shaw, Wayne ;

Law, Gordon ;

Desai, Mehul ;

Matthews, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) :644-657

[64] Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure [J].

Packer, Milton ;

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Pocock, Stuart J. ;

Carson, Peter ;

Januzzi, James ;

Verma, Subodh ;

Tsutsui, Hiroyuki ;

Brueckmann, Martina ;

Jamal, Waheed ;

Kimura, Karen ;

Schnee, Janet ;

Zeller, Cordula ;

Cotton, Daniel ;

Bocchi, Edimar ;

Boehm, Michael ;

Choi, Dong-Ju ;

Chopra, Vijay ;

Chuquiure, Eduardo ;

Giannetti, Nadia ;

Janssens, Stefan ;

Zhang, Jian ;

Juanatey, Jose R. Gonzalez ;

Kaul, Sanjay ;

Brunner-La Rocca, Hans-Peter ;

Merkely, Bela ;

Nicholls, Stephen J. ;

Perrone, Sergio ;

Pina, Ileana ;

Ponikowski, Piotr ;

Sattar, Naveed ;

Senni, Michele ;

Seronde, Marie-France ;

Spinar, Jindrich ;

Squire, Iain ;

Taddei, Stefano ;

Wanner, Christoph ;

Zannad, Faiez .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) :1413-1424

[65] Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy [J].

Palmer, Biff F. ;

Clegg, Deborah J. .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (08) :1284-1291

[66] Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records [J].

Pearson-Stuttard, Jonathan ;

Bennett, James ;

Cheng, Yiling J. ;

Vamos, Eszter P. ;

Cross, Amanda J. ;

Ezzati, Majid ;

Gregg, Edward W. .

LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (03) :165-173

[67] Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy [J].

Perkovic, V. ;

Jardine, M. J. ;

Neal, B. ;

Bompoint, S. ;

Heerspink, H. J. L. ;

Charytan, D. M. ;

Edwards, R. ;

Agarwal, R. ;

Bakris, G. ;

Bull, S. ;

Cannon, C. P. ;

Capuano, G. ;

Chu, P. -L. ;

De Zeeuw, D. ;

Greene, T. ;

Levin, A. ;

Pollock, C. ;

Wheeler, D. C. ;

Yavin, Y. ;

Zhang, H. ;

Zinman, B. ;

Meininger, G. ;

Brenner, B. M. ;

Mahaffey, K. W. ;

McGuire, Darren K. ;

Holman, Rury ;

Home, Philip ;

Scharfstein, Dan ;

Parfrey, Patrick ;

Shahinfar, Shahnaz ;

August, Phyllis ;

Chang, Tara ;

Sinha, Arjun D. ;

Januzzi, James ;

Kolansky, Daniel ;

Amerena, John ;

Hillis, Graham ;

Gorelick, Philip ;

Kissela, Brett ;

Kasner, Scott ;

Lindley, Richard ;

Fulcher, Greg ;

Ounadjela, Souhila ;

Hufert, Karina ;

von Ingersleben, Gabriele ;

Gaglia, Jason ;

Harris, Ronald ;

Hudson, Margo ;

Turchin, Alexander ;

Cheifetz, Adam .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24) :2295-2306

[68] Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis [J].

Qian, Dan ;

Zhang, Tiantian ;

Zheng, Peiying ;

Liang, Zhuoru ;

Wang, Sen ;

Xie, Jingmei ;

Zhao, Lina ;

Zhang, Ying ;

Situ, Bing .

DIABETES THERAPY, 2018, 9 (05) :1945-1958

[69] Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors [J].

Qiu, Mei ;

Ding, Liang-Liang ;

Zhang, Miao ;

Zhou, Hai-Rong .

DIABETES & VASCULAR DISEASE RESEARCH, 2021, 18 (02)

[70] Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial [J].

Roden, Michael ;

Merker, Ludwig ;

Christiansen, Anita Vedel ;

Roux, Flavien ;

Salsali, Afshin ;

Kim, Gabriel ;

Stella, Peter ;

Woerle, Hans J. ;

Broedl, Uli C. .

CARDIOVASCULAR DIABETOLOGY, 2015, 14

← 1 2 3 4 5 6 7 8 9 10 →